Research
[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer
The Lancet · By Linda Mileshkin & George Au-Yeung ·
The Brief
- Endometrial cancer is the most common gynaecological cancer in high-income countries and the sixth most common cancer in women worldwide.
- Both incidence and mortality of endometrial cancer are increasing, making it one of few cancers with this trend.
- A Lancet comment discusses sacituzumab tirumotecan in previously treated endometrial cancer.
Why it matters
Rising incidence and mortality make effective treatment options for patients whose cancer has already been treated an important concern for oncology researchers and clinicians.
Who’s affected
- gynaecological oncologists and clinicians
- oncology researchers
- #endometrial cancer
- #gynaecological cancer
- #oncology
- #sacituzumab tirumotecan
- #clinical comment
Endometrial cancer is the most common gynaecological cancer in high-income countries, the sixth most common cancer in women worldwide,1 and one of few cancers for which both the incidence and mortality rate are increasing.2,3 Although 75% of endometrial cancers present with…